Eary J F, Pollard K R, Durack L D, Bice A N, Lewellen T K, Matthews D, Press O W, Nelp W B, Appelbaum F R, Bernstein I
Department of Radiology, University of Washington, Seattle 98195.
Med Phys. 1994 Jul;21(7):1157-62. doi: 10.1118/1.597343.
The biodistribution of a trace-labeled I-131 antibody is used to predict the biodistribution of a high dose I-131 antibody for therapy. Internal radiation dose estimates derived from the trace-labeled antibody have been used to determine the I-131 doses in a phase I escalating dose therapy trial for hematologic malignancy. To confirm the hypothesis that the distribution of a trace- and high-dose labeled antibodies are similar, both trace (7-11 mCi, 259-407 MBq) and high-dose (100-800 mCi, 3700-29600 MBq) I-131 radiolabeled antibody infusion were imaged in 12 patients who were treated for leukemia or lymphoma. With specialized imaging techniques using lead attenuation sheets, clearance data from organs were obtained from serial gamma camera images. Biological clearance half times of I-131 from both trace and therapy level doses were in agreement. An exception was a patient who developed human antimouse antibody before therapy, and subsequently had rapid clearance of the therapy dose. The method was feasible, yielded reproducible results, and provided critical data for relating therapy toxicity to radiation absorbed dose estimates.
微量标记的I-131抗体的生物分布用于预测高剂量I-131抗体治疗时的生物分布。源自微量标记抗体的内辐射剂量估计值已用于在血液系统恶性肿瘤的I期剂量递增治疗试验中确定I-131剂量。为了证实微量和高剂量标记抗体的分布相似这一假设，对12例接受白血病或淋巴瘤治疗的患者进行了微量（7-11毫居里，259-407兆贝可）和高剂量（100-800毫居里，3700-29600兆贝可）I-131放射性标记抗体输注的成像。使用铅衰减片的专门成像技术从连续的γ相机图像中获取器官的清除数据。微量剂量和治疗剂量水平的I-131的生物清除半衰期一致。有一名患者在治疗前产生了人抗鼠抗体，随后治疗剂量快速清除，这是一个例外情况。该方法可行，结果可重复，并为将治疗毒性与辐射吸收剂量估计值相关联提供了关键数据。
